5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Interventional Cardiology
In treating heart disease, the shift toward interventional cardiology has significantly changed how cardiovascular conditions are managed. Procedures like balloon angioplasty and stent insertion are now commonplace in clinical practice, allowing for the treatment of coronary artery blockages without the need for open-heart surgery. These minimally invasive interventions have reduced recovery times and improved patient outcomes. In addition, emerging technologies, such as intravascular imaging techniques, help cardiologists visualize blockages with precision, guiding interventions more effectively. As the field advances, the integration of robotics and next-generation devices promises even better outcomes, offering patients faster recovery and longer-lasting results.
John R Doty
Intermountain Medical Center, United States
Trevor Tucker
Dynamic Vascular Resolution Inc., Canada
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Fatima Michelle Villa Jimenez
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico
Mancilla Sandoval Yoana Tenneth
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian FederationSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Surgical options for aortic valve preservation
John R Doty, Intermountain Medical Center, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina